Skip to Main Content

Paper Details

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.
Clin Cancer Res
3
2023
Adults, Children, DNA methyltransferase, GISTs, Guadecitabine, HLRCC, HLRCC-RCC, HLRCC-associated Renal Cell Carcinoma, KIT, PBMCs, Paraganglioma, Pheochromocytoma, RCC, SDH, SDH-Deficient GIST, Succinate, Succinate dehydrogenase, Succinate dehydrogenase deficient (dSDH) tumors, dSDH GIST, dSDH tumors, decitabine, dinucleotide, gastrointestinal stromal tumors, guadecitabine, hereditary leiomyomatosis, neutropenia, paraganglioma, patient, patients, peripheral blood mononuclear cells, pheochromocytoma, platelet derived growth factor receptor alpha, platelet derived growth factor receptor alpha mutations, renal cell cancer, renal cell carcinoma
Author NameAffiliation
Jack F ShernCenter for Cancer Research, National Cancer Institute
Seth M Steinberg
Seth M Steinberg
Karel PacakEunice Kennedy Shriver National Institute of Child Health and Human Development
Jonathan K KillianFoundation Medicine, Inc.
Jonathan K KillianFoundation Medicine, Inc.
William Marston Linehan
Markku Miettinen
Markku Miettinen
Lee J HelmanOsteosarcoma Institute
Lee J HelmanOsteosarcoma Institute
Paul S Meltzer
Paul S Meltzer
Brigitte C WidemannCenter for Cancer Research, National Cancer Institute
  • 1 - 14

Datasets

Release 1.2